WHO Solidarity Trial of Repurposed Antiviral Drugs in COVID-19 Reports Little to No Effect
WHO Solidarity Trial of Repurposed Antiviral Drugs in COVID-19 Reports Little to No Effect on Mortality, Severity, and Length of Hospital Stay.
11,266 adult patients with COVID-19 were enrolled in 405 hospitals in 30 countries. Patients were randomized equally to receive any one of the four locally available drug regimens, Remdesivir, Hydroxychloroquine, Lopinavir or Interferon beta-1a and no antiviral.
1,253 deaths occurred at a median 8 days after enrollment. No study drug reduced deaths, progression to ventilation for respiratory failure, or length of hospitalization.
- These results are consistent with meta-analysis of mortality in all major trials.
- The study was supported by the World Health Organization (NCT04315948).
- Study results have not undergone peer-review.
Source: Pre-print server medRxiv (ISRCTN83971151), not certified by peer-review.